Uromigos Live 2023: Where Do We Stand With PARP Inhibitors in Prostate Cancer?

During the second-annual Uromigos Live & Unplugged event, Brian Rini, MD, FASCO; Michael Morris, MD; Rana McKay, MD; Tanya Dorff, MD; and Neeraj Agarwal, MD, break down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials.

They also consider the relevant radiographic progression-free survival and hazard ratio data.

View the second prostate cancer session of the day on radioligand therapy.